Diurnal Variation in Tear Osmolarity

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Ophthalmic Consultants of Long Island.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Allergan
Information provided by (Responsible Party):
Ophthalmic Consultants of Long Island
ClinicalTrials.gov Identifier:
NCT01321424
First received: March 21, 2011
Last updated: November 16, 2012
Last verified: March 2011

March 21, 2011
November 16, 2012
March 2011
January 2013   (final data collection date for primary outcome measure)
The measured difference in Tear Osmolarity during the course of the day to support clinical diagnosis and differentiate between aqueous-deficiency and meibomian gland disease. [ Time Frame: 1 Day (AM and PM Diurnal) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01321424 on ClinicalTrials.gov Archive Site
Ocular Improvement [ Time Frame: 31 Days ] [ Designated as safety issue: No ]
Improvement in Ocular Surface Disease Index, Best Corrected Visual Acuity, Uncorrected Visual Acuity, Slit Lamp Exam, Schirmer test, Lissamine green conjunctival staining, Fluorescein corneal staining and Tear Break Up Time
Ocular Improvement [ Time Frame: 31 Days ] [ Designated as safety issue: No ]
Improvement in OSDI, BCVA, UCVA, Slit Lamp Exam, Schirmer test, Lissamine green conjunctival staining, Fluorescein corneal staining and TBUT
Not Provided
Not Provided
 
Diurnal Variation in Tear Osmolarity
Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology

The purpose of this study is to measure the change in Tear Osmolarity during the course of the day to support clinical diagnosis of aqueous deficiency or meibomian gland disease and differentiate between the two forms of dry eye.

The premise of this study is that dry eye disease, specifically tear osmolarity, changes during the course of the day based on the etiology of the dry eye and that aqueous-deficiency dry eye will worsen during the course of the day while meibomian gland deficiency will stabilize or possibly even improve during the course of the day.

Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Primary care facility

Dry Eye Disease
Not Provided
  • Aqueous Dificiency Dry Eye
  • Meibomian Gland Disease Dry Eye
  • Normal Eye
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
January 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy males and females ≥ 18 years old
  2. Negative urine pregnancy results for females of childbearing potential
  3. Able to read and sign an informed consent form and show willingness to comply with the study protocol visits and procedures
  4. Has 20/40 BCVA or better in at least one eye
  5. Does not currently wear contact lenses
  6. For Aqueous-Deficiency Group:

    • Has symptoms of Dry Eye
    • Schirmer testing ≤ 10 mm
    • Tear Break Up Time ≤ 8 seconds
    • Conjunctival staining ≥ 1+
    • Meibomian gland inspissations ≤ 1+
    • No lid thickening, lid erythema, or thickened, turbid meibomian gland secretions
  7. For Meibomian Gland Disease Group:

    • Has symptoms of Dry Eye
    • Schirmer testing ≥ 10 mm
    • Tear Break Up Time ≤ 8 seconds
    • Conjunctival staining ≥ 1+
    • Meibomian gland inspissations ≥ 2+
  8. For Normal Group:

    • Has no symptoms of Dry Eye
    • Schirmer testing > 10 mm
    • Tear Break Up Time > 8 seconds
    • No or trace Conjunctival staining
    • No Meibomian gland inspissations

Exclusion Criteria:

  1. Any topical medication within the last three months, except for artificial tears
  2. Unable to discontinue use of artificial tears during the course of the day for Visit 2
  3. Any Systemic disease, which in the opinion of the Investigator, may affect ocular health or confound study results
  4. Any active ocular disease other than Dry Eye Disease, Meibomian Gland Disease or Sjogren's Syndrome, which in the opinion of the Investigator, may affect ocular health or confound study results
  5. Clinically significant lid or conjunctival abnormalities, neovascularization, corneal scars or corneal opacities
  6. Clinically significant limbal or bulbar injection, or corneal staining not due to DES
  7. Has worn hard or rigid gas permeable contact lenses within 1 year
  8. Has worn soft contact lenses within 1 week
  9. Has had eye surgery or an eye injury within 6 months
  10. Positive urine pregnancy results for females of childbearing potential
  11. Any changes in current medication within 30 days of Visit 2 or anticipated change during course of study, which in the opinion of the Investigator may confound study results
Both
18 Years and older
Yes
Contact: Joan Fredrickson 516-705-7140 jfredrickson@ocli.net
United States
 
NCT01321424
ALRGN01
No
Ophthalmic Consultants of Long Island
Ophthalmic Consultants of Long Island
Allergan
Principal Investigator: Eric D Donnenfeld, MD Ophthalmic Consultants of Long Island
Study Director: Barbara Burger, RN Ophthalmic Consultants of Long Island
Ophthalmic Consultants of Long Island
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP